Clinical trial · no report yet · Phase 2
NCT05226117
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
- NCT05226117 ↗
- Completed
- IRCCS San Raffaele
- 43 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 34 | |
| YouTube | 6 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- SURE-01_An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Sacituzumab Govitecan, Before Radical Cystectomy, for Patients With Muscleinvasive Bladder Cancer Who Cannot Receive or Refuse Cisplatin-based Chemotherapy
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Urothelial Carcinoma
- Interventions
- Sacituzumab govitecan
- Arms
- Treatment arm · Experimental
- Enrollment
- 44
- Primary outcomes
- Pathological complete response
- Sponsor
- IRCCS San Raffaele with High Research
- Start
- Mar 23, 2022
- Primary completion
- Sep 24, 2025
- Results posted
- No
- Registry record
- NCT05226117 · updated Mar 27, 2026
Publications
linked from the registry- Necchi A, de Jong JJ, Maiorano BA, Proudfoot JA, Basile G, Cigliola A, Mercinelli C, Tateo V, Piacentini M, Crupi E, Pastorino GL, Latini G, Tomasi E, Davicioni E, Moschini M, Brembilla G, Colecchia M, de Cobelli F, Ross JS, Madison R, Tambaoan CFB, Briganti A, Montorsi F. Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial. J Clin Oncol. 2026 Jul 20;44(21):2017-2028. doi: 10.1200/JCO-26-00142. Epub 2026 May 31. PubMed 42218654